



Soft Tissue Bioscaffold

Clinical Case Series

Pilonidal Sinus Disease





Myriad Matrix[™]

Clinical Case Series: **Pilonidal Sinus Disease**



Wide excision and fasciocutaneous flap advancement


20-Year-old male. Two-year history of pilonidal sinus managed with incision and drainages. Previously underwent an excision with primary midline closure ~1 year ago, resulted in wound dehiscence and subsequent chronic draining purulent sinuses. Procedure involved full thickness excision of affected area (~12 x 6 x 5 cm). Myriad Matrix (3-layer, 10 x 10 cm) placed in the defect prior to fasciocutaneous flap mobilization. Silver dressing placed over incision followed by an incisional NPWT. Wound fully healed at 3 weeks and remained healed at 10 weeks.¹



Flap Advancement







CC.0026

8-49%

The rate of surgical complications of pilonidal sinus disease has been reported to be between^{2,3}

Myriad Matrix[™]

Clinical Case Series: Pilonidal Sinus Disease

Wide excision and closure

15-Year-old male. Initial abscess 8 months prior, with incision and drainage performed. Cyst excision 2 months later with plan for secondary intent healing with NPWT. Experienced severe pain with each dressing change and debridement in which anesthesia was required. Patient opted for wide excision and closure. **Myriad Matrix** (5-layer, 10 x 20 cm) sutured to the defect, then incisional NPWT. Defect healed at 5 weeks.



Initial Defect



ision & Graft Placem (arrow)



Wick-assisted Closure





Week 5



CC.0028

Recurrent pilonidal sinus excision and reconstruction

37-year-old male. Chronic recurrent pilonidal cyst for 20 years. Prior management included multiple prior surgical procedures. Underwent wide excision of the lesion. **Myriad Matrix** (10 x 10 cm, 3-layer) was applied under a contact layer and secondary dressings including ABD pads. At day 5, **Myriad Matrix** was observed to be incorporating. At day 12, epithelialization at the edges could be seen along with residual **Myriad** in the defect center. At day 20, functional granular neodermis was visible and the sutures removed. No complications were reported. At week 10, the wound was 90% epithelialized and the patient went on to fully heal with no recurrence as of 6 months.



CC.0079

Myriad Matrix[™]

Clinical Case Series: Pilonidal Sinus Disease

Minimally invasive technique

15-Year-old male. Four plus year history of PSD. Prior management included several incision and drainages, as well as a full excision and Karydakis flap 2 years ago. 4 Weeks prior to surgery the patient had an incision and drainage with placement of a drain. Prior to placement of Myriad Matrix, a curettage of the 8 cm long sinus was performed. Myriad Matrix (10 x 10 cm, 5-layer) was rolled following rehydration, passed through the sinus tract and anchored to the openings with suture. The wound was dressed with a petrolatum-based contact layer and dry gauze. At day 19, the openings of the sinus tract had completely healed. A bedside ultrasound was performed and revealed no fluid in the sinus tract. At long-term 23-week follow-up there was no recurrence and the sinus tract remined closed with no complications.⁴



CC.0041

- Chaffin A et al. Surgical reconstruction of pilonidal sinus disease with concomitant extracellular matrix graft placement: a case series. Journal of Wound Care; Vol 30, No. 7, July 2021. https://www.magonlinelibrary.com/doi/full/1012968/jowc.202130.Sup7S28
 Alvandipour, M. et al. Comparison of Limberg flap and Karydakis flap surgery for the treatment of patients with pilonidal sinus disease: A single-blinded parallel randomized study. Ann. Coloproctol. 35, 313–318 (2019).
- A test et al. Short and long-term results of the Karydakis flap versus the Limberg flap for treating pilonidal sinus disease: a prospective randomized study. Am J Surgery. 2011; 202 568-573
 Holloway, B. (2021). Minimally Invasive Closure for Recurrent Pilonidal Sinus Using Extracellular Matrix Graft: A Case Report. Symposium on Advanced Wound Care Fall, 2021 (October 29-31), Las Vegas, NV. Available at: https://aroabio.com/wp-content/uploads/2021/11/Holloway_2021-SAWC-Fall-13-Oct-2021-FINAL.pdf

RX Only. Intended for viewing by healthcare providers only. Results may vary. The content herein does not constitute or contain medical advice. Any medical information provided in the content is of a general nature and is not intended to be a substitute for medical advice, diagnosis or treatment of a physician or other qualified health provider.

Prior to use of this device, be sure to read the complete information on how to use this device including Warnings, Precautions, Contraindications and Instructions for Use and all other package inserts supplied with the product.

Not all devices are registered and approved for sale in all countries or regions and indications for use may vary by country or region. Please contact your local representative for more information.

For product questions, sampling needs, or detailed questions concerning our products, please contact us:

For the US: P 1-877627-6224 | E customerservice@aroa.com

For all other countries: call your local representative or email globalsales@aroacom

AROA™, Myriad Matrix™ and AROA ECM™ are trademarks of Aroa Biosurgery Limited.



www.aroa.com

MKT.1773.01 | © December 2023